3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Carcinoma, Non-Small-Cell Lung
37
Lung Neoplasms
21
Squamous Cell Carcinoma of Head and Neck
18
Urinary Bladder Neoplasms
8
Oropharyngeal Neoplasms
8
Uterine Cervical Neoplasms
7
Parkinson Disease 4, Autosomal Dominant Lewy Body
6
Pancreatic Neoplasms
6
Neoplasms
6
Colorectal Neoplasms
6
Cholangiocarcinoma
6
Carcinoma
6
Neoplasm Metastasis
5
Mesothelioma, Malignant
5
Endometrial Neoplasms
5
Biliary Tract Neoplasms
5
Neoplasms by Site
4
Nasopharyngeal Carcinoma
4
Mouth Neoplasms
4
Head and Neck Neoplasms
4
Carcinoma, Squamous Cell
4
Triple Negative Breast Neoplasms
3
Ovarian Neoplasms
3
Medulloblastoma
3
Laryngeal Neoplasms
3
Esophageal Squamous Cell Carcinoma
3
Colonic Neoplasms
3
Tongue Neoplasms
2
Small Cell Lung Carcinoma
2
Salivary Gland Neoplasms
2
Interventions
pembrolizumab
3
fludarabine
2
aldesleukin
2
Cyclophosphamide
2
enfortumab vedotin
1
cabozantinib
1
Specimen Handling
1
Radiosurgery
1
Radiation Dose Hypofractionation
1
Nivolumab
1
Mitomycin
1
Magnetic Resonance Spectroscopy
1
Ipilimumab
1
Gemcitabine
1
Fulvestrant
1
Fluorouracil
1
Continuous Positive Airway Pressure
1
Cisplatin
1
CTLA-4 Antigen
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Urogenital Neoplasms
×
Cisplatin
×
30 days
×
Clear all
NCT07566156
2026-06-08
EV-309
Astellas Pharma Inc
Phase 3
Recruiting
390 enrolled